- Current report filing (8-K)
June 04 2010 - 6:03AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 4, 2010 (May 29,
2010)
SHENGTAI
PHARMACEUTICAL, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of
incorporation)
|
000-51312
(Commission
File
Number)
|
54-2155579
(IRS
Employer
Identification
No.)
|
Changda
Road East
Development
District, Changle County
Shandong,
PRC
(Address
of principal executive offices)
|
262400
(Zip
Code)
|
Registrant’s
telephone number, including area code:
011-86-536-6295802
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 DFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item
5.02
Departure of Directors
or Principal Officers; Election of Directors; Appointment of
Principa
l
Officers
On May
29, 2010, Mr. Changxin Li resigned from his position as a director and a member
of each of the Audit Committee and the Compensation Committee of the Board
because of personal reasons. The Board of Directors accepted his
resignation on June 1, 2010. We provided Mr. Li with a copy of this disclosure
before its filing with the SEC. We requested that Mr. Li provide us with a
letter stating whether or not he agrees with the above statements, and we
received a letter from Mr. Li stating that he agrees with the above
statements. A copy of his letter is filed as an exhibit to this
report.
On June
1, 2010, Mr. Yaojun Liu was appointed as a director, Chairman of the Audit
Committee and a member of the Compensation Committee and the
Nominating/Corporate Governance Committee. Mr. Liu meets the criteria of an
“audit committee financial expert” as set forth under the applicable rules of
the SEC.
On June
1, 2010, Mr. Fei He was appointed as a director, Chairman of the Compensation
Committee and a member of the Audit Committee and the Nominating/Corporate
Governance Committee.
On June
1, 2010, Mr. Winfred Lee, our existing director, was appointed as Chairman of
the Nominating/Corporate Governance Committee of the Company. Mr. Lee has been a
Director of the Company since June 22, 2007 and is a member of the Company’s
Audit Committee and the Compensation Committee.
Item
8.01 Other Events
On June 1, 2010, the Board of Directors
decided to establish a Nominating/Corporate Governance Committee and appointed
Messrs. Winfred Lee (Chairman), Yaojun Liu and Fei He as members of the
Nominating/Corporate Governance Committee. The Board of Directors adopted the
Charter of the Nominating/Corporate Governance Committee, which is filed as an
exhibit to this report.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
99.1
|
Letter
dated June 4, 2010 from Changxin Li to the Company.
|
|
99.2
|
Charter
of the Nominating/Corporate Governance
Committee.
|
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICAL, INC.
|
|
|
|
|
|
|
|
Dated:
June 4, 2010
|
|
|
|
By:
/s/ Qingtai Liu
|
|
|
Name:
Qingtai Liu
|
|
|
Title:
Chief Executive Officer
|
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Aug 2023 to Aug 2024